This doctor's BPC-157 warning is spot-on, actually

What does this video actually claim?

Dr. Fernando Pérez Galaz argues that BPC-157, a peptide sold widely online, lacks human clinical trials despite 30 years of animal research. He claims most studies come from one lab, warns about potential cancer risks, and criticizes vendors who don't screen for risk factors.

The video takes a skeptical stance on the peptide's safety profile. Pérez Galaz points out that the same vascular growth mechanisms that supposedly heal tissue could theoretically promote tumor growth.

He's not anti-peptide science, just pro-evidence. The message is clear: buyer beware for unregulated peptide markets.

Does the research really come from one lab?

Yes, and this is a huge red flag. The overwhelming majority of BPC-157 studies trace back to researchers at the University of Zagreb, particularly Predrag Sikiric's group. This concentration of research in a single lab is unusual for any therapeutic compound.

A 2022 review by Kang et al. in the International Journal of Molecular Sciences noted this exact problem. When one research group dominates the literature on a compound, it raises questions about reproducibility and bias.

Independent replication is the cornerstone of good science. BPC-157 hasn't had enough of it. Most peptides with legitimate therapeutic potential attract research from multiple institutions worldwide.

Are there really zero human trials?

Correct. Despite being discovered in the 1990s, BPC-157 has never completed a proper randomized controlled trial in humans. The research remains stuck in animal models after three decades.

PubMed searches reveal studies in rats, mice, and rabbits showing wound healing and gastric protection. But translating animal results to humans is notoriously unreliable. The failure rate for drugs moving from animal studies to human efficacy is around 90%.

Compare this to legitimate peptides like liraglutide, which has dozens of human trials including the SCALE program (Pi-Sunyer et al., NEJM, 2015) showing 8.4% weight loss at 56 weeks. That's what real evidence looks like.

Could BPC-157 actually promote cancer growth?

This concern isn't paranoid speculation. BPC-157 appears to promote angiogenesis (blood vessel formation), which is exactly how tumors spread and metastasize. The same mechanism that might heal your torn muscle could feed a hidden cancer.

The peptide's proposed benefits include increased VEGF (vascular endothelial growth factor) expression. But VEGF is also a key player in cancer progression. This is why anti-VEGF drugs like bevacizumab are used to treat certain cancers.

Without proper safety studies, we don't know if BPC-157 could accelerate existing malignancies. That's especially concerning given how casually it's sold online without medical screening.

What should you actually know about peptide vendors?

Most online peptide sellers operate in a regulatory gray area, selling "research chemicals" not intended for human use. Yet customers clearly buy them for self-administration, creating a dangerous disconnect.

Legitimate medical peptides like semaglutide require prescriptions, medical supervision, and come from FDA-approved facilities. Underground peptides like BPC-157 have no such oversight for purity, dosing, or safety.

Dr. Pérez Galaz is right to ask whether vendors screen for cancer risk factors. They don't. Most don't even verify you're an adult before selling powerful bioactive compounds.